Peter Rossing, MD, DMSc
Head of Research Professor,
Steno Diabetes Center Copenhagen
Featured in the Session: Rethinking RAAS: Novel Strategies to Target a Classic Pathway in Diabetic Kidney Disease
When
Saturday, June 6
at 8:00 a.m. CT
Where
Hall E-2 (Level 1)
Ernest N. Morial Convention Center
What is your presentation about?
Aldosterone is causing inflammation and fibrosis leading to kidney and heart problems. Traditionally we have used mineralocorticoid receptor antagonists to reduce damage caused by excess aldosterone, but a new option is aldosterone synthase inhibitors (ASI) and they are currently tested for treatment of resistant hypertension, heart failure and chronic kidney disease (CKD).
How do you hope your presentation will impact diabetes research or care?
Raise awareness of the need to reduce the damage caused by aldosterone and tell about the new studies ongoing with this class of drugs, and talk about potential benefits and safety.
How did you become involved with this area of diabetes research or care?
I have worked with treatment and prevention of CKD in diabetes by blocking the renin angiotensin aldosterone system for many years and was involved in the first study in CKD with an ASI.